J
Julie C. Locklear
Researcher at Janssen Pharmaceutica
Publications - 3
Citations - 211
Julie C. Locklear is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Olanzapine & Atypical antipsychotic. The author has an hindex of 3, co-authored 3 publications receiving 204 citations.
Papers
More filters
Journal ArticleDOI
Assessment of compliance with antipsychotic treatmentand resource utilization in a medicaid population
TL;DR: Evaluated patients diagnosed as having schizophrenia or bipolar disorder with prescribed oral atypical and conventional antipsychotic agents and the corresponding impact on resource utilization found partial compliance was associated with an increased risk of hospitalization and switching or augmentation of therapy when compared with being compliant.
Journal ArticleDOI
Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA
TL;DR: Longacting risperidone may be a cost saving therapeutic option for patients with schizophrenia from a healthcare system perspective and predicted to result in better clinical outcomes and lower total healthcare costs than its comparators.
Journal ArticleDOI
Different Approaches To Valuing the Lost Productivity of Patients with Migraine
TL;DR: This was the first study to retrospectively estimate lost productivity of patients with migraine using the FCA methodology, and demonstrates that depending on the assumptions and illustrations employed, the F CA can yield lost productivity estimates that vary greatly as a percentage of the HCAestimate.